CCS
AMAG

Crosspoint Capital Strategies’s AMAG Pharmaceuticals AMAG Stock Holding History

Crosspoint Capital Strategies’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-99,274
Closed -$3.46M – 125
2016
Q4 		$3.46M Buy
+99,274
New +$2.97M 3.07% 14
2015
Q3 		– Sell
-152
Closed -$10K – 924
2015
Q2 		$10K Buy
+152
New +$9.56K ﹤0.01% 535
2015
Q1 		– Sell
-138
Closed -$6K – 794
2014
Q4 		$6K Buy
+138
New +$4.99K ﹤0.01% 568

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crosspoint Capital Strategies's AMAG Position: Q1 2017 in Review

Crosspoint Capital Strategies sold out of AMAG Pharmaceuticals (AMAG) in Q1 2017, closing a stake of 99,274 shares — an estimated $3.46M sold.

Crosspoint Capital Strategies first reported a position in AMAG in Q4 2014 and held it in 3 quarters. The position peaked at $3.46M in Q4 2016. 185 funds tracked by Wall St. Rank hold AMAG as of Q1 2017.

  • Crosspoint Capital Strategies reported no remaining AMAG Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 99,274 AMAG Pharmaceuticals shares in Q1 2017, an estimated $3.46M.
  • Crosspoint Capital Strategies first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Crosspoint Capital Strategies's AMAG Pharmaceuticals position peaked at $3.46M in Q4 2016.
  • 185 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2017, filed 11 May 2017.